Evidence map›Paper›PMID 37919456›Full record

ArticleBone marrow transplantation2024

Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy.

Ana Benzaquén, Estela Giménez, Gloria Iacoboni, Manuel Guerreiro, Rafael Hernani, Eliseo Albert, Cecilia Carpio, Aitana Balaguer, Ariadna Pérez, Carlos S de la Asunción and 17 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Immune Monitoring Goes Viral - Torque Teno Virus for Immunologic Risk Stratification After Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
  4. Torque Teno Virus-guided monitoring of immunosuppressive therapy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 1 country.

Ana Benzaquén *Haematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.ORCID 0000-0003-4015-0831
Estela GiménezMicrobiology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Gloria IacoboniHaematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Manuel GuerreiroHaematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.ORCID 0000-0001-5978-2578
Rafael Hernani *Haematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Eliseo AlbertMicrobiology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Cecilia CarpioHaematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0001-9346-0134
Aitana BalaguerHaematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Ariadna PérezHaematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Carlos S de la AsunciónMicrobiology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Mario Andrés Sánchez-SalinasHaematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Pedro ChorãoHaematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.ORCID 0000-0001-6741-971X
José Luis PiñanaHaematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.ORCID 0000-0001-8533-2562
Francisco BeasHaematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Juan MontoroHaematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.ORCID 0000-0003-0024-8068
Juan Carlos Hernández-BoludaHaematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.ORCID 0000-0002-4289-3113
Ana FacalHaematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Blanca FerrerHaematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Marta VillalbaHaematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Paula AmatHaematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
María Dolores GomézMicrobiology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Diana CamposHaematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
María José TerolHaematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
Jaime SanzHaematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.ORCID 0000-0001-6934-4619
Pere BarbaHaematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. pebarba@vhebron.net.
David NavarroMicrobiology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.ORCID 0000-0003-3010-4110
Carlos SolanoHaematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.ORCID 0000-0003-3702-0817
INCLIVA Health Research Institute · ESHospital Universitari i Politècnic La Fe · ESUniversitat de València · ESVall d'Hebron Hospital Universitari · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Torque Teno Virus (TTV) is a single-stranded circular DNA virus which has been identified as a surrogate marker of immune competence in transplantation. In this study we investigated the dynamics of plasma TTV DNAemia in 79 adult patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory large B-cell lymphoma, also evaluating the impact of TTV on immunotoxicities, response and survival outcomes. After lymphodepleting therapy, TTV DNA load was found to decrease slightly until reaching nadir around day 10, after which it increased steadily until reaching maximum load around day 90. TTV DNA load < 4.05 log10 copies/ml at immune effector cell-associated neurotoxicity syndrome (ICANS) onset identified patients at risk of progressing to severe forms of ICANS (OR 16.68, P = 0.048). Finally, patients who experienced falling or stable TTV DNA load between lymphodepletion and CAR-T infusion had better progression-free survival than those with ascending TTV DNA load (HR 0.31, P = 0.006). These findings suggest that TTV monitoring could serve as a surrogate marker of immune competence, enabling predictions of CAR-T efficacy and toxicity. This could pave the way for the development of TTV-guided therapeutic strategies that modulate clinical patient management based on plasma TTV load, similar to suggested strategies in solid organ transplant recipients.

Indexed as

DNA Virus InfectionsReceptors, Chimeric AntigenTorque teno virusAdultBiomarkersDNA, ViralHumansPrognosisViral LoadBiomarkersDNA, ViralReceptors, Chimeric Antigen

Identifiers

PMID37919456
OpenAlexW4388223579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.